Newsgather

diabete

مستقر124 خبر12 مصادرآخر تحديث: قبل 11 ساعة

أحدث الأخبار

Australia warns on Ozempic, Mounjaro eye disorder risk
يتطور
صحة·قبل 14 ساعةملخص الذكاء الاصطناعي

Australia warns on Ozempic, Mounjaro eye disorder risk

Australia's Therapeutic Goods Administration (TGA) has warned about a "rare but severe" eye disorder, non-arteritic anterior ischaemic optic neuropathy (NAION), linked to type 2 diabetes and obesity treatments like Ozempic and Mounjaro. The warning, based on 36 reported cases, advises patients to seek urgent medical attention for sudden vision loss but not to stop treatment without consulting a doctor.

G
Guardian World
3 د قراءة
Novo Nordisk Sues Eli Lilly Over 'Misleading' Weight-Loss Drug Ads
يتطور
Business·قبل 3 أيامملخص الذكاء الاصطناعي

Novo Nordisk Sues Eli Lilly Over 'Misleading' Weight-Loss Drug Ads

Novo Nordisk is suing Eli Lilly, alleging "false and misleading" advertisements for its weight-loss and anti-diabetes treatments, Zepbound and Mounjaro. Novo Nordisk claims Lilly used outdated studies comparing its highest doses against lower doses of Novo Nordisk's drugs, creating a deceptive impression of superiority. Eli Lilly defends its ads, citing the Surmount-5 trial as the only direct comparison.

G
Guardian Business
1 د قراءة
ADA Deputy Editors Publish Preprint After Organization Refuses to Run Critical Articles on New Orleans Incident
يتطور
علوم·قبل 5 أيامملخص الذكاء الاصطناعي

ADA Deputy Editors Publish Preprint After Organization Refuses to Run Critical Articles on New Orleans Incident

Deputy editors of Diabetes Care have released a preprint containing an editorial and seven opinion pieces after the American Diabetes Association refused to publish them. The articles detail new allegations surrounding the removal of five prominent scientists from the ADA's annual meeting in New Orleans for distributing criticism of the Trump administration's attacks on scientific research.

A
Ars Technica
7 د قراءة
GLP-1 Drug Implant Aims to Solve Long-Term Weight Loss Maintenance
يتطور
صحة·11‏/7‏/2026ملخص الذكاء الاصطناعي

GLP-1 Drug Implant Aims to Solve Long-Term Weight Loss Maintenance

Vivani Medical is developing a GLP-1 implant for long-term weight loss maintenance, potentially reducing side effects and injection fatigue. The device, an experimental semaglutide implant, aims for twice-yearly or annual administration, complementing existing GLP-1 treatments. However, it faces clinical trials, regulatory hurdles, and questions about cost and physician adoption.

C
CNBC US Markets
8 د قراءة